The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A phase Ib/II study of second-line therapy with panitumumab, irinotecan, and everolimus (PIE) in metastatic colorectal cancer with KRAS wild type (WT).
A. R. Townsend
No relevant relationships to disclose
L. Pirc
No relevant relationships to disclose
J. Hardingham
No relevant relationships to disclose
C. S. Karapetis
No relevant relationships to disclose
N. C. Tebbutt
Consultant or Advisory Role - Amgen (U)
N. Singhal
No relevant relationships to disclose
T. J. Price
Consultant or Advisory Role - Amgen (U)